Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Klaria Pharma Holding AB: Klaria Interim Report Q1 2023

Klaria Pharma Holding
Download the release

Summary of the Interim Report

Net sales of 6.5 MSEK (0.0 MSEK)

Other income amounted to 0.1 MSEK (0.1 MSEK)

First quarter of 2023

- R&D costs for the period amounted to 8.6 MSEK (17.2 MSEK)

- Profit after tax amounted to -5.4 MSEK (-20.3 MSEK)

- Earnings per share for the quarter amounted to -0.06 SEK (-0.37 SEK)

- Cash flow from operating activities amounted to -9.1 MSEK (-19.8 MSEK)

- Cash and cash equivalents on the balance sheet date amounted to 13.1 MSEK (23.0 MSEK)

- Cash and cash equivalents on the balance sheet date amounted to 70.7 MSEK (72.1 MSEK)

- Klaria receives payment of 2.6 MSEK from Imbrium Therapeutics within the R&D collaboration for Adrenaline Alginate Film

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.